MGRX (Mangoceuticals) Tariff Resilience Score: 4/10 (As of Jul. 08, 2026)


MGRX Mangoceuticals Inc MGRX
22 GF Score
Price $0.38
GF Value $0.32
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Mangoceuticals Tariff Resilience Score?

Mangoceuticals MGRX +0.60% 22 Tariff Resilience Score is 4 as of Jul. 08, 2026. GuruFocus rates MGRX with a GF Score™ of 22/100 and a GF Value™ of $0.32 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 672 Healthcare Providers & Services companies, Mangoceuticals ranks better than 75.6% on this metric.

Mangoceuticals has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Mangoceuticals has Significant reliance on imported raw materials for production. Global sales increase exposure to tariffs. Limited pricing power and historical tariff changes have affected margins.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Mangoceuticals might have Average Resilient.

Mangoceuticals  (NAS:MGRX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Mangoceuticals Tariff Resilience Score Related Terms

MGRX vs WLSS, ACON, VSEE: Tariff Resilience Score Comparison

For the Health Information Services subindustry, Mangoceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mangoceuticals Tariff Resilience Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Mangoceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Mangoceuticals's Tariff Resilience Score falls into.


MGRX
22GF Score
Mangoceuticals Inc MGRX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Mangoceuticals (MGRX) has a Tariff Resilience Score of 4 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Mangoceuticals ranks #164 out of 672 companies in the Healthcare Providers & Services industry, placing it in the top 24.4%.
Is Mangoceuticals' Tariff Resilience Score too high?
Mangoceuticals' current Tariff Resilience Score is 4. Based on the distribution chart, Mangoceuticals ranks #164 out of 672 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Mangoceuticals has a GF Score™ of 22/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mangoceuticals' Tariff Resilience Score compare to WLSS and ACON?
According to the Healthcare Providers & Services industry distribution chart, Mangoceuticals ranks #164 out of 672 companies for Tariff Resilience Score. This places Mangoceuticals in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Healthcare Providers & Services company?
A good Tariff Resilience Score depends on the Healthcare Providers & Services industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Mangoceuticals's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangoceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mangoceuticals (MGRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $0.38 — trading 17.2% above its estimated fair value. The current Tariff Resilience Score is 4. Mangoceuticals' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Mangoceuticals (MGRX), the current Tariff Resilience Score is 4 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mangoceuticals (MGRX) Overvalued in 2026?

Based on GuruFocus' analysis, Mangoceuticals stock appears to be overvalued. The current stock price of $0.38 is trading 17.2% above its estimated GF Value™ of $0.32. GuruFocus considers Mangoceuticals to be Modestly Overvalued.

Key valuation signals for MGRX:

  • Tariff Resilience Score: 4
  • GF Value™: $0.32 vs. price of $0.38 (17.2% above fair value)
  • GF Score™: 22/100 with 2 warning signs

No single metric tells the full story. See the MGRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mangoceuticals Business Description

Address 17130 Dallas Parkway, Suite 240, Dallas, TX, USA, 75248
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
22GF Score

Get the complete analysis for MGRX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price
$0.32
GF Value